Product Description

CD16a (FcγRIIIa, 176F) is a low-affinity IgG Fc receptor mainly expressed on NK cells and macrophages, playing a central role in ADCC. The 176F variant exhibits lower affinity for IgG Fc compared to the 176V variant, resulting in reduced ADCC efficacy and relatively poorer response to antibody-based therapies. This variant is highly frequent in the population, and its low-affinity characteristic influences individual responses to antibody drugs, underscoring the importance of CD16a genotyping in personalized therapy.

Screeningbio’s TR-FRET Human CD16a (FcγRⅢA, 176F) Binding Assay Kit can be used to screen for IgGs that bind to Human CD16a (FcγRⅢA, 176F), and is suitable for functional evaluation of ADCC and ADCP activities of antibody drug candidates. CD16a (FcγRⅢA, 176F) is hereinafter referred to as CD16a (176F). This kit is a competitive immunoassay developed using TR-FRET technology, characterized by simplicity, rapidity, high accuracy, and good reproducibility.

The basic principle of this method is as follows: an anti‑Tag1 antibody conjugated to TR‑FRET Solar Eu*1 specifically recognizes the CD16a (176F) protein bearing Tag1. Human IgG conjugated to TR‑FRET LA*2 binds to the CD16a (176F) protein, bringing the Solar Eu donor and LA acceptor into close proximity. Upon excitation by an external light source, fluorescence resonance energy transfer occurs between the donor and acceptor. The binding level between CD16a (176F) and Human IgG can be determined by measuring the signal intensity at a specific wavelength (665 nm). Free Human IgG or proteins with a human Fc tag in the sample compete with Human IgG‑LA for the binding sites on CD16a (176F), and the TR‑FRET signal intensity is inversely proportional to the concentration of free Human IgG or proteins with a human Fc tag in the sample.